Clinical Trial Update: A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating MCMV5322A/MCMV3068A for the prevention of Cytomegalovirus disease in high-risk kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• MCMV5322A/MCMV3068A

Snippet

Sponsor: Genentech, Inc. | Conditions: Cytomegalovirus Infections | Phase 2 | Status: COMPLETED